

# CITATION REPORT

List of articles citing

Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets

DOI: 10.1038/bjp.2008.141

British Journal of Pharmacology, 2008, 154, 787-96.

**Source:** <https://exaly.com/paper-pdf/43648453/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
43	Treatment of pediatric pulmonary hypertension. <i>Vascular Health and Risk Management</i> , <b>2009</b> , 5, 509-24	4.4	17
42	Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. <i>International Journal of Impotence Research</i> , <b>2009</b> , 21, 221-7	2.3	80
41	Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. <i>Hypertension</i> , <b>2009</b> , 53, 1091-7	8.5	19
40	Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2009</b> , 36, 358-66	3	5
39	Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. <i>Urology</i> , <b>2009</b> , 74, 216-21	1.6	10
38	Vardenafil: efficacy, tolerability and future directions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2009</b> , 5, 553-62	5.5	3
37	Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle. <i>European Journal of Pharmacology</i> , <b>2010</b> , 637, 171-7	5.3	19
36	Pulmonary hypertension in dogs: diagnosis and therapy. <i>Veterinary Clinics of North America - Small Animal Practice</i> , <b>2010</b> , 40, 623-41	2.4	92
35	Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 93-133	3.2	45
34	Different effects of different phosphodiesterase type-5 inhibitors in pre-eclampsia. <i>Pregnancy Hypertension</i> , <b>2011</b> , 1, 231-7	2.6	5
33	Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 47-84	3.2	41
32	Role of phosphodiesterases in adult-onset pulmonary arterial hypertension. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 279-305	3.2	6
31	Tadalafil in pulmonary hypertension: may be more than seen?. <i>Human and Experimental Toxicology</i> , <b>2012</b> , 31, 1186-7	3.4	
30	Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension. <i>Scientific World Journal, The</i> , <b>2012</b> , 2012, 718279	2.2	11
29	Vardenafil ameliorates calcium mobilization in pulmonary artery smooth muscle cells from hypoxic pulmonary hypertensive mice. <i>Archives of Medical Research</i> , <b>2012</b> , 43, 265-73	6.6	4
28	Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 990-8	3.8	4
27	Cardiovascular Disease, Lymphoproliferative Disorders, and Thymomas. <b>2012</b> , 257-268		6

26	Pediatric pulmonary arterial hypertension. <i>Current Hypertension Reports</i> , <b>2013</b> , 15, 606-13	4.7	4
25	Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil. <i>Respiratory Physiology and Neurobiology</i> , <b>2013</b> , 186, 61-4	2.8	6
24	Scleroderma therapy: clinical overview of current trends and future perspective. <i>Rheumatology International</i> , <b>2013</b> , 33, 1-18	3.6	12
23	The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. <i>Cardiovascular Research</i> , <b>2013</b> , 99, 395-403	9.9	45
22	An evaluation of vardenafil as a calcium channel blocker in pulmonary artery in rats. <i>Indian Journal of Pharmacology</i> , <b>2014</b> , 46, 185-90	2.5	4
21	Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model. <i>Cardiovascular Drugs and Therapy</i> , <b>2014</b> , 28, 45-51	3.9	4
20	Advances in targeting cyclic nucleotide phosphodiesterases. <i>Nature Reviews Drug Discovery</i> , <b>2014</b> , 13, 290-314	64.1	488
19	Echinacoside induces rat pulmonary artery vasorelaxation by opening the NO-cGMP-PKG-BKCa channels and reducing intracellular Ca <sup>2+</sup> levels. <i>Acta Pharmacologica Sinica</i> , <b>2015</b> , 36, 587-96	8	15
18	Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1165-73	2.8	2
17	The L-type Ca(2+) Channel Blocker Nifedipine Inhibits Mycelial Growth, Sporulation, and Virulence of <i>Phytophthora capsici</i> . <i>Frontiers in Microbiology</i> , <b>2016</b> , 7, 1236	5.7	4
16	Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2017</b> , 25, 254-259	1.8	7
15	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , <b>2017</b> , 8, 99179-99202	3.3	28
14	Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 203, 107393	13.9	9
13	Tadalafil for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 929-937	4	12
12	Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. <i>Congenital Heart Disease</i> , <b>2019</b> , 14, 246-255	2.1	4
11	Manipulating fenestrations in young and old liver sinusoidal endothelial cells. <i>American Journal of Physiology - Renal Physiology</i> , <b>2019</b> , 316, G144-G154	5.1	28
10	Cardiovascular Disease. <b>2020</b> , 250-257		3
9	[Organ Bath Experiments on Human Pulmonary Vessels: Assessment of Drug Efficacy for Treatment of Pulmonary Arterial Hypertension]. <i>Pneumologie</i> , <b>2021</b> , 75, 369-376	0.5	

8	The wHole Story About Fenestrations in LSEC. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 735573	4.6	3
7	Sexuelle Funktionsstörungen. <b>2012</b> , 1085-1096		
6	Platelets in pulmonary hypertension: a causative role or a simple association?. <i>Iranian Journal of Pediatrics</i> , <b>2012</b> , 22, 145-57	1	13
5	High Dose Vardenafil Blunts the Hypertensive Effects of Toll-Like Receptor 3 Activation During Pregnancy. <i>Frontiers in Virology</i> , <b>2021</b> , 1,		
4	The NO / cGMP / PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.		1
3	Quinazoline-Based Human Phosphodiesterase 5 Inhibitors Exhibited a Selective Vasorelaxant Effect on Rat Isolated Pulmonary Arteries Involving NO-sGC-cGMP Pathway and Calcium Inhibitory Effects.		0
2	Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects. <b>2022</b> , 107111		0
1	Impaired platelet function and thrombus formation in PDE5A-deficient mice.		0